AtaGenix

Caplacizumab

  • 1
  • 2
ATAD00272
-
+
futures
Inquiry
  • Product Details
  • Bioactivity
  • Chemistry
  • How to order
  • Instructions
Catalog No.icon
ATAD00272
INN (International Nonproprietary Name)icon
Caplacizumab
Purityicon
>95%
SDS-PAGE imageicon
    Concentrationicon
    1.6 mg/ml
    Formulationicon
    20mM Citric acid,6.2% sucrose,0.01% Tween 80
    Sourceicon
    CHO cells
    Endotoxin levelicon
    Please contact with the lab for this information.
    Noteicon
    For research use only .
    Descriptionicon
    Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,6 and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
    Alternative namesicon
    ALX-0081,PMP12A2h1-linker AAA-PMP12A2h1,caplacizumab-yhdp
    Specificity target name;speciesicon
    VWF A1 domain[Homo sapiens]
    Speciesicon
    Humanized
    Receptor identificationicon
    VH-VH
    MVicon
    30 kDa
    CASicon

    915810-67-2
    Storageicon
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Store at +4°C short term (1-2 weeks).
    Store at -20 °C 12 months.
    Store at -80°C long term.

    Guarantee and Disclaimer:

    After receiving the product, if finds that the product is mismatched, damaged or missing components, please keep the original package and submit the objection to the company by mail within seven working days. Failure to file an objection within the time limit is considered qualified.

    When the buyer keeps the product, it should be kept in accordance with the storage conditions shown in the product label and the manual. If the product quality is caused by improper storage, it will not be guaranteed.

    When the buyer tests the product, they should be submitted by the beginning of use when found the quality issue, rather than when the product was used or used up, in order to prepare our products for recycling and confirm the quality of the products. If it is the quality problem, our company is responsible for exchange or return. In the event of a claim, our company will compensate the discretion within the scope of the product price limit and will not accept any part of the value of the product itself. Since the date of receipt, the product has not been reflected for more than three months and should not be returned.

    The products provided by our company are for research use only and should not be used for clinical diagnosis or treatment. If a unit or individual changes the use of our products without authorization, we will not bear any responsibility.